Inventiva SA ADR IVA 深 滬
等待開盤 01-28 09:30:00 美东时间
6.86
-0.210
-2.97%
華盛通- 最 高7.10
- 今 開7.05
- 成交量 47.16万股
- 最 低 6.76
- 昨 收 7.07
- 總市值 9.54亿
- 52周最高 7.9825
- 市盈率 靜 --
- 換手率 0.34%
- 52周最低 2.2312
- 委 比 -9.04%
- 總股本 1.39亿
- 歷史最高 19.064
- 量 比 0.55
- 振 幅 4.81%
- 歷史最低 1.53
- 每 手 1
- 風險率 1.10%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 算力基建再提速！Galaxy Digital 涨超37%，获批电力容量翻番；创新药企IBRX大涨近137%
算力基建再提速！Galaxy Digital 周涨超37%，获批电力容量翻番；创新药企IBRX周涨近137%，在研创新药获批上市>>
01-17 10:31
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Leerink Partners Initiates Coverage On Inventiva with Outperform Rating, Announces Price Target of $12
Leerink Partners analyst Thomas Smith initiates coverage on Inventiva (NASDAQ:IVA) with a Outperform rating and announces Price Target of $12.
01-12 20:37
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Shares of LexinFintech Holdings Ltd – ADR (NASDAQ:LX) rose sharply in pre-marke...
2025-11-24 18:23
Inventiva S.A reports 9M results
Inventiva S.A (IVA): Revenues for the first nine months of 2025 amounted to €4.5 million, compared to none generated for the same period in 2024. Cash and cash equivalents at €97.6 million, and €24.7 ...
2025-11-22 05:05
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Guggenheim Maintains Buy on Inventiva, Lowers Price Target to $11
Guggenheim analyst Seamus Fernandez maintains Inventiva (NASDAQ:IVA) with a Buy and lowers the price target from $13 to $11.
2025-11-18 22:16
Inventiva Secures $172.5M from Full Exercise of Underwriters’ Option
Inventiva ( ($IVA) ) just unveiled an update. On November 17, 2025, Inventiva a...
2025-11-17 19:29
Inventiva Prices U.S. Offering Of 38.96M ADSs At $3.85 Each; Settlement Expected November 17
Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated
2025-11-13 22:24
Inventiva announces $125M U.S. public offering of ADSs
Inventiva (IVA) plans to offer ~$125 American Depositary Shares. Each ADS will represent one new ordinary share of the company. The underwritten public offering will be conducted in the United States ...
2025-11-13 05:42
